S&P 500   5,067.00 (-0.22%)
DOW   38,853.28 (-0.31%)
QQQ   435.95 (-0.38%)
AAPL   180.79 (-1.01%)
MSFT   407.51 (+0.01%)
META   486.87 (-0.04%)
GOOGL   135.98 (-2.09%)
AMZN   173.86 (+0.18%)
TSLA   203.68 (+1.98%)
NVDA   783.71 (-0.42%)
NIO   5.49 (-5.02%)
AMD   176.06 (-1.09%)
BABA   75.10 (-3.32%)
T   17.02 (+1.13%)
F   12.37 (+3.08%)
MU   89.71 (-2.33%)
CGC   3.41 (-3.40%)
GE   155.13 (+0.74%)
DIS   110.70 (+1.17%)
AMC   4.87 (+1.25%)
PFE   27.16 (+1.00%)
PYPL   60.52 (+0.60%)
XOM   104.18 (+0.14%)
S&P 500   5,067.00 (-0.22%)
DOW   38,853.28 (-0.31%)
QQQ   435.95 (-0.38%)
AAPL   180.79 (-1.01%)
MSFT   407.51 (+0.01%)
META   486.87 (-0.04%)
GOOGL   135.98 (-2.09%)
AMZN   173.86 (+0.18%)
TSLA   203.68 (+1.98%)
NVDA   783.71 (-0.42%)
NIO   5.49 (-5.02%)
AMD   176.06 (-1.09%)
BABA   75.10 (-3.32%)
T   17.02 (+1.13%)
F   12.37 (+3.08%)
MU   89.71 (-2.33%)
CGC   3.41 (-3.40%)
GE   155.13 (+0.74%)
DIS   110.70 (+1.17%)
AMC   4.87 (+1.25%)
PFE   27.16 (+1.00%)
PYPL   60.52 (+0.60%)
XOM   104.18 (+0.14%)
S&P 500   5,067.00 (-0.22%)
DOW   38,853.28 (-0.31%)
QQQ   435.95 (-0.38%)
AAPL   180.79 (-1.01%)
MSFT   407.51 (+0.01%)
META   486.87 (-0.04%)
GOOGL   135.98 (-2.09%)
AMZN   173.86 (+0.18%)
TSLA   203.68 (+1.98%)
NVDA   783.71 (-0.42%)
NIO   5.49 (-5.02%)
AMD   176.06 (-1.09%)
BABA   75.10 (-3.32%)
T   17.02 (+1.13%)
F   12.37 (+3.08%)
MU   89.71 (-2.33%)
CGC   3.41 (-3.40%)
GE   155.13 (+0.74%)
DIS   110.70 (+1.17%)
AMC   4.87 (+1.25%)
PFE   27.16 (+1.00%)
PYPL   60.52 (+0.60%)
XOM   104.18 (+0.14%)
S&P 500   5,067.00 (-0.22%)
DOW   38,853.28 (-0.31%)
QQQ   435.95 (-0.38%)
AAPL   180.79 (-1.01%)
MSFT   407.51 (+0.01%)
META   486.87 (-0.04%)
GOOGL   135.98 (-2.09%)
AMZN   173.86 (+0.18%)
TSLA   203.68 (+1.98%)
NVDA   783.71 (-0.42%)
NIO   5.49 (-5.02%)
AMD   176.06 (-1.09%)
BABA   75.10 (-3.32%)
T   17.02 (+1.13%)
F   12.37 (+3.08%)
MU   89.71 (-2.33%)
CGC   3.41 (-3.40%)
GE   155.13 (+0.74%)
DIS   110.70 (+1.17%)
AMC   4.87 (+1.25%)
PFE   27.16 (+1.00%)
PYPL   60.52 (+0.60%)
XOM   104.18 (+0.14%)

Akero Therapeutics (AKRO) Earnings Date, Estimates & Call Transcripts

$27.29
-0.01 (-0.04%)
(As of 01:57 PM ET)
Skip Charts & View Estimated and Actual Earnings Data

AKRO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AKRO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Akero Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.89)($0.89)($0.89)
Q2 20241($0.89)($0.89)($0.89)
Q3 20241($0.94)($0.94)($0.94)
Q4 20241($0.94)($0.94)($0.94)
FY 20244($3.66)($3.66)($3.66)

AKRO Earnings Date and Information

Akero Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 15th, 2024 based off prior year's report dates.

Akero Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/15/2024
Estimated)
------- 
11/13/2023Q3 2023($0.70)($0.71)($0.01)($0.71)--
8/11/2023Q2 2023($0.61)($0.60)+$0.01($0.60)--
5/15/2023Q1 2023($0.62)($0.55)+$0.07($0.55)--
3/17/2023Q4 2022($0.78)($0.49)+$0.29($0.49)--
11/4/2022Q3 2022($0.73)($0.92)($0.19)($0.92)--
8/4/2022Q2 2022($0.85)($0.77)+$0.08($0.77)--
5/6/2022Q1 2022($0.85)($0.74)+$0.11($0.74)--
2/25/2022Q4 2021($0.81)($0.93)($0.12)($0.93)--    
11/12/2021Q3 2021($0.91)($0.70)+$0.21($0.70)--
8/12/2021Q2 2021($0.72)($0.83)($0.11)($0.83)--
5/12/2021Q1 2021($0.90)($0.43)+$0.47($0.43)--
3/15/2021Q4 2020($0.59)($0.86)($0.27)($0.86)--












Akero Therapeutics Earnings - Frequently Asked Questions

When is Akero Therapeutics's earnings date?

Akero Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 15th, 2024 based off last year's report dates. Learn more on AKRO's earnings history.

How much profit does Akero Therapeutics generate each year?

Akero Therapeutics (NASDAQ:AKRO) has a recorded net income of -$112.03 million. AKRO has generated -$2.35 earnings per share over the last four quarters.

What is Akero Therapeutics's EPS forecast for next year?

Akero Therapeutics's earnings are expected to decrease from ($2.82) per share to ($3.34) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:AKRO) was last updated on 2/28/2024 by MarketBeat.com Staff